Crescendo widens pivotal solid tumour therapy trial
The CB307 study expansion involves the addition of a new pembrolizumab combination cohort
Read More
Tag: tumour
New technique developed to ‘listen in’ on cancer cells
Understanding how cells communicate could reveal how tumours are able to evade the immune system and become resistant to treatments.
Read More
GSK, Lyell join forces for cancer cell therapies
The partnership will develop new technologies to improve cell therapies for cancer patients.
Read More
New cancer research could help boost immunotherapy treatments
Scientists have found a way to pull down the protective wall that surrounds tumours, potentially re-exposing them to the killing power of the immune system.
Read More
Pairing targeted drugs could overcome breast, lung cancer treatment resistance
The new data could broaden the clinical use of palbociclib – and other drugs that work in the same way – beyond breast cancer to include many other tumour types as well.
Read More
NICE recommends Roche’s Tecentriq for metastatic NSCLC
The recommendation is for the drug in combination with Avastin (bevacizumab), carboplatin and paclitaxel.
Read More
New breast cancer blood test could help spot relapse two years earlier
The blood test was able to detect 89% of all relapses, on average an impressive 8.9 months quicker than imaging.
Read More
NICE final guidance published for Cimzia
For adults who have failed to respond to, or are unsuitable for, other systemic therapies.
Read More
Genomics England completes first phase of liquid biopsy study
The results will enable researchers to perform an objective technology evaluation of the various market offerings in liquid biopsy in the second stage.
Read More
IGEM gets further funding for cancer drugs
The £750,000 grant will go to developing novel IgE antibodies, targeting HER2.
Read More
Keytruda reduces risk of death compared to chemo
Merck’s Keytruda has been found to reduce risk of death by 31% compared to chemotherapy, when used in previously treated patients with advanced esophageal or esophagogastric junction carcinoma, whose tumours express PD-L1.
Read More
Early access to Tecentriq combination granted through EAMS
UK patients with a form of advanced lung cancer will soon be able to access the immunotherapy drug Tecentriq in combination with Avastin, carboplatin and paclitaxel through the Early Access to Medicines Scheme (EAMS).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
